Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Outterson

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
American Journal of Law & Medicine|August 14, 2008
Should access to medicines and TRIPS flexibilities be limited to specific diseases?Kevin Outterson
The New England Journal of Medicine|December 27, 2013
The Drug Quality and Security Act--mind the gapsKevin Outterson
The New England Journal of Medicine|November 9, 2012
Regulating compounding pharmacies after NECCKevin Outterson
The New England Journal of Medicine|July 3, 2014
Clinical trial transparency--antidote to weaker off-label-promotion rules?Kevin Outterson
The Medical Journal of Australia|September 7, 2004
Free trade in pharmaceuticalsM Kevin Outterson
Health Affairs (Project Hope)|May 4, 2016
Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive PolicyKevin Outterson, Anthony McDonnell
Nature Reviews. Drug Discovery|February 15, 2023
Trends in the global antibiotics marketJacob Madden, Kevin Outterson
Health Affairs (Project Hope)|October 6, 2016
Antimicrobial Resistance: The Authors ReplyKevin Outterson, Anthony McDonnell
Health Affairs (Project Hope)|September 8, 2010
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goalsAaron S Kesselheim, Kevin Outterson
Yale Journal of Health Policy, Law, and Ethics|March 9, 2011
Improving antibiotic markets for long-term sustainabilityAaron S Kesselheim, Kevin Outterson
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
American Journal of Law & Medicine|August 14, 2008
Should access to medicines and TRIPS flexibilities be limited to specific diseases?Kevin Outterson
The New England Journal of Medicine|December 27, 2013
The Drug Quality and Security Act--mind the gapsKevin Outterson
The New England Journal of Medicine|November 9, 2012
Regulating compounding pharmacies after NECCKevin Outterson
The New England Journal of Medicine|July 3, 2014
Clinical trial transparency--antidote to weaker off-label-promotion rules?Kevin Outterson
The Medical Journal of Australia|September 7, 2004
Free trade in pharmaceuticalsM Kevin Outterson
Health Affairs (Project Hope)|May 4, 2016
Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive PolicyKevin Outterson, Anthony McDonnell
Nature Reviews. Drug Discovery|February 15, 2023
Trends in the global antibiotics marketJacob Madden, Kevin Outterson
Health Affairs (Project Hope)|October 6, 2016
Antimicrobial Resistance: The Authors ReplyKevin Outterson, Anthony McDonnell
Health Affairs (Project Hope)|September 8, 2010
Fighting antibiotic resistance: marrying new financial incentives to meeting public health goalsAaron S Kesselheim, Kevin Outterson
Yale Journal of Health Policy, Law, and Ethics|March 9, 2011
Improving antibiotic markets for long-term sustainabilityAaron S Kesselheim, Kevin Outterson
Pageof 8